EMEA-001757-PIP02-15-M03
EMEA-001757-PIP02-15-M03
EMEA-001757-PIP02-15-M03
Procedural advice on the accelerated assessment of marketing authorisation applications pursuant to Article 44 (3) of Regulation (EU) No 2019/6
Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043
Valproate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0043
Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0043
Herbal medicinal product: Fumariae herbaArray, F: Assessment finalised
Public-health advice during COVID-19 pandemic
Simplified summary - EMA/ECDC/EFSA fourth joint report on the integrated analysis of the antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA (JIACRA IV)
Multi-agency report highlights importance of reducing antibiotic use
EMA/ECDC/EFSA fourth joint report on the integrated analysis of the antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA (JIACRA IV)